EN DE
Watch PT Diastika Biotekindo Tbk for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PT Diastika Biotekindo Tbk (CHEK) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of PT Diastika Biotekindo Tbk stock IDR 78, price IDR 100, that is 22.3% below the price, quality 43 out of 100. Rating: overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID

PD PT Diastika Biotekindo Tbk logo Thin data Nov 4, 2026

PT Diastika Biotekindo Tbk

CHEK · JK
Expensive, weak quality

Our calculation puts a fair price 22% below what the stock costs today.

Low debt
Revenue last quarter +37% vs. a year ago.
Quality 43/100
Expensive Growth (revenue YoY +30.0 %/yr in IDR)
Thin margins · 3.5% net margin (TTM)
Mixed vs. peers (5/12)
Fair value 77.75 IDR · Overvalued
Narrow moat 36/100 · thin data
Thin data
⚠ Small free float
Watch PT Diastika Biotekindo Tbk for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

210.00 IDR 98.00 IDR Fair Value 77.75 IDR Jul 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

16‑month range 98.00 IDR – 210.00 IDR · fair‑value band 56.25 IDR – 99.70 IDR · the 100.00 IDR price screens above the 77.75 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow PT Diastika Biotekindo Tbk in your weekly email

Every Wednesday you see whether PT Diastika Biotekindo Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Diastika Biotekindo Tbk engages in the sale of disposable or consumable medical goods and diagnostic equipment in Indonesia. It operates through Clinical Diagnostic Group and Life Science Group segments. The company offers various products for detecting, diagnosing, and monitoring human disease.

Show moreShow less

It also provides life science products that are processed from biological products. In addition, the company engages in general trading, laboratory equipment, research, medicine, export and import, pharmaceutical chemicals, services, electronics, and industrial activities.

PT Diastika Biotekindo was founded in 1989 and is headquartered in Jakarta Timur, Indonesia. PT Diastika Biotekindo Tbk is a subsidiary of PT Optel Investama Mulia.

Stock analysis

PT Diastika Biotekindo Tbk (CHEK) currently trades at 100.00 IDR, while our model-based Fair Value estimate is 77.75 IDR, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 120.48 IDR per share, and 4 of the 15 models we run sit above the 100.00 IDR price.

Bear case: the Dividend Discount group reads lowest at 9.64 IDR, and 11 of the 15 models stay below the price. Data coverage for this calculation is low.

Scenario range: 56.25 IDR (bear) to 99.70 IDR (bull), the price of 100.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

PT Diastika Biotekindo Tbk reported revenue of 201B IDR in FY2025 versus 129B IDR in FY2023, a compound +24.9%/yr. Reported net income was 14.0B IDR in FY2025, compounding +1.6%/yr from FY2023.

Key figures

Market cap 411B IDR (≈ $22.8M) Micro · P/S ratio 1.83 · Dividend yield 0.8% · Net margin 3.5% · Return on equity 3.8% · Return on assets (EBIT) 14.2% (3-year average) · Operating margin 6.2% · Revenue (TTM) 225B IDR.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).

What moves the price

The share trades about 46% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −22%, CHEK screens richer than that median.

Fair Value models

Bear 56.25 IDR Fair Value 77.75 IDR Bull 99.70 IDR
Price 100.00 IDR · Downside -22.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 37.61 IDR 41.75 IDR 45.15 IDR 71
Residual Income 37.50 IDR 37.70 IDR 40.17 IDR 69
EV/EBIT 76.34 IDR 100.26 IDR 124.19 IDR 66
All 15 models by family
Earnings-Based
Graham-Dodd 23.18 IDR 161.67 IDR 226.88 IDR 57
Lynch FV 66.25 IDR 94.64 IDR 123.03 IDR 55
PEG = 1.0 66.25 IDR 94.64 IDR 123.03 IDR 52
EPV 37.61 IDR 41.75 IDR 45.15 IDR 71
Dividend Discount
Gordon GGM 5.80 IDR 9.95 IDR 13.15 IDR 62
DDM Multi-Stage 5.80 IDR 9.32 IDR 10.68 IDR 61
Multiples
P/E Multiple 56.25 IDR 75.00 IDR 93.75 IDR 63
P/S Multiple 43.47 IDR 57.96 IDR 72.44 IDR 58
P/B Multiple 173.19 IDR 230.92 IDR 288.66 IDR 55
EV/EBIT 76.34 IDR 100.26 IDR 124.19 IDR 66
EV/Revenue 55.80 IDR 77.75 IDR 99.70 IDR 54
Asset-Based
NCAV (Graham) 26.53 IDR 40.20 IDR 50.25 IDR 54
Economic Profit
Residual Income 37.50 IDR 37.70 IDR 40.17 IDR 69
ROIC Compounder 37.61 IDR 41.75 IDR 45.15 IDR 66
Growth Earnings
Growth-Adj P/E 84.33 IDR 120.48 IDR 156.62 IDR 61

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 45
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 85
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 68
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

CHEK screens overvalued: fair value 22% below the price. Compare with McKesson Corporation →

Compare PT Diastika Biotekindo Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks

Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Bottom 25%
Fair Value upside −22.3% · Below median
Profitability
Return on equity (12 months) 3.8% · Below median
Return on assets 5.4% · Top 25%
Net margin (12 months) 3.5% · Above median
Operating margin (12 months) 6.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 36.8% · Top 25%
Dividend yield (12 months) 0.8% · Bottom 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 1.95× · Priciest 25%
P/S (12 months) 1.83× · Priciest 25%
EV/EBITDA 9.7× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 38
FUTURE (revenue growth)100 · sector 24
PAST (return on equity)15 · sector 28
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)16 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$17.16 HK$51.48 +200% vs CHEK
Jointown Pharmaceutical Group 600998 ¥5.24 ¥11.56 +121% vs CHEK
Shanghai Pharmaceuticals Holding 601607 ¥16.76 ¥35.78 +113% vs CHEK
China National Medicines Corporation 600511 ¥29.29 ¥58.47 +100% vs CHEK
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥20.09 ¥26.64 +33% vs CHEK
Cencora, Inc COR $333.56 $341.58 +2% vs CHEK
Henry Schein, Inc HSIC $86.05 $78.69 −9% vs CHEK
McKesson Corporation MCK $1,061 $822.74 −22% vs CHEK
Galenica AG GALE CHF 89.45 CHF 61.79 −31% vs CHEK
Cardinal Health, Inc CAH $271.72 $163.14 −40% vs CHEK

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PT Diastika Biotekindo Tbk: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PT Diastika Biotekindo Tbk Fair Value". https://www.fairvalue-calculator.com/stock/CHEK

Frequently asked questions

Is PT Diastika Biotekindo Tbk (CHEK) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 77.75 IDR versus a price of 100.00 IDR, about 22% lower (overvalued).
What is the fair value of CHEK?
Our model-based fair value for PT Diastika Biotekindo Tbk is 77.75 IDR (as of Nov 4, 2026), built from audited fundamentals. The current price: 100.00 IDR.
What is the quality score of CHEK?
PT Diastika Biotekindo Tbk has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Diastika Biotekindo Tbk (CHEK)?
Our model-based price target is the fair value of 77.75 IDR (as of Nov 4, 2026) from 15 valuation models. Cautious scenario 56.25 IDR, optimistic scenario 99.70 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Diastika Biotekindo Tbk stock forecast for 2026?
Our models put fair value at 77.75 IDR, about 22% lower versus a price of 100.00 IDR (overvalued). Cautious scenario 56.25 IDR, optimistic scenario 99.70 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Diastika Biotekindo Tbk (CHEK)?
PT Diastika Biotekindo Tbk reported trailing-twelve-month revenue of about 225B IDR (latest available figure, as of Nov 4, 2026).
Does PT Diastika Biotekindo Tbk pay a dividend?
PT Diastika Biotekindo Tbk currently shows a dividend yield of 0.80% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of PT Diastika Biotekindo Tbk (CHEK)?
PT Diastika Biotekindo Tbk has a dividend yield of 0.8%.
What is the intrinsic value of PT Diastika Biotekindo Tbk (CHEK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Diastika Biotekindo Tbk it is 77.75 IDR per share (as of Nov 4, 2026), against a price of 100.00 IDR. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is PT Diastika Biotekindo Tbk stock overvalued or undervalued in 2026?
As of Nov 4, 2026, CHEK trades above its calculated fair value: price 100.00 IDR, fair value 77.75 IDR, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHEK?
No. The price is what the market pays today (100.00 IDR); the fair value is what the company's own numbers justify (77.75 IDR). For PT Diastika Biotekindo Tbk the two are 22.25 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Diastika Biotekindo Tbk worth?
The market values PT Diastika Biotekindo Tbk at about 411B IDR (market capitalisation, as of Nov 4, 2026). Per share that is 100.00 IDR; our models calculate a fair value of 77.75 IDR per share.
What do the bullish and bearish scenarios say about CHEK?
Our models span a range for PT Diastika Biotekindo Tbk: cautious scenario 56.25 IDR, base 77.75 IDR, optimistic 99.70 IDR per share (as of Nov 4, 2026, price 100.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT Diastika Biotekindo Tbk (CHEK)?
Balance-sheet figures for PT Diastika Biotekindo Tbk (as of Nov 4, 2026): return on equity 3.8%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is CHEK from its 52-week high?
PT Diastika Biotekindo Tbk trades at 100.00 IDR, about 46% below its 52-week high of 185.00 IDR and 2% above the low of 98.00 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 77.75 IDR is for.
Which stocks are comparable to PT Diastika Biotekindo Tbk?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Diastika Biotekindo Tbk stock attractive at the current price?
The data as of Nov 4, 2026: price 100.00 IDR, calculated fair value 77.75 IDR (−22%), Quality Score 43/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHEK calculated?
We run PT Diastika Biotekindo Tbk through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 77.75 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. PT Diastika Biotekindo Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Diastika Biotekindo Tbk (CHEK)?
The closing price on Nov 6, 2026 was 100.00 IDR. Our model-based fair value is 77.75 IDR, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Diastika Biotekindo Tbk right now?
Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of PT Diastika Biotekindo Tbk

How large is the market capitalisation of PT Diastika Biotekindo Tbk (CHEK)?
The market capitalisation of PT Diastika Biotekindo Tbk is 411B IDR (≈ $22.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Diastika Biotekindo Tbk (CHEK)?
The price-to-sales ratio of PT Diastika Biotekindo Tbk is 1.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of PT Diastika Biotekindo Tbk (CHEK)?
The dividend yield of PT Diastika Biotekindo Tbk is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PT Diastika Biotekindo Tbk (CHEK)?
The net margin of PT Diastika Biotekindo Tbk is 3.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Diastika Biotekindo Tbk (CHEK)?
The return on equity (ROE) of PT Diastika Biotekindo Tbk is 3.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Diastika Biotekindo Tbk (CHEK)?
On an EBIT basis the return on assets of PT Diastika Biotekindo Tbk is 14.2% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Diastika Biotekindo Tbk (CHEK)?
The operating margin of PT Diastika Biotekindo Tbk is 6.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Diastika Biotekindo Tbk (CHEK)?
Revenue at PT Diastika Biotekindo Tbk is growing +36.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Diastika Biotekindo Tbk (CHEK)?
Earnings per share at PT Diastika Biotekindo Tbk are growing −29.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch PT Diastika Biotekindo Tbk in the live analysis

One click puts PT Diastika Biotekindo Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.